- Home
- EQ vs MNOV Comparison
EQ vs MNOV Comparison
Compare EQ & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- MNOV
- Stock Information
- Founded
- EQ 2017
- MNOV 2000
- Country
- EQ United States
- MNOV United States
- Employees
- EQ N/A
- MNOV N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- EQ Health Care
- MNOV Health Care
- Exchange
- EQ Nasdaq
- MNOV Nasdaq
- Market Cap
- EQ 67.9M
- MNOV 65.7M
- IPO Year
- EQ 2018
- MNOV 2005
- Fundamental
- Price
- EQ $1.50
- MNOV $1.24
- Analyst Decision
- EQ Hold
- MNOV Strong Buy
- Analyst Count
- EQ 2
- MNOV 2
- Target Price
- EQ $1.00
- MNOV $7.00
- AVG Volume (30 Days)
- EQ 2.5M
- MNOV 65.3K
- Earning Date
- EQ 11-12-2025
- MNOV 11-12-2025
- Dividend Yield
- EQ N/A
- MNOV N/A
- EPS Growth
- EQ N/A
- MNOV N/A
- EPS
- EQ N/A
- MNOV N/A
- Revenue
- EQ $16,553,000.00
- MNOV $134,599.00
- Revenue This Year
- EQ N/A
- MNOV N/A
- Revenue Next Year
- EQ N/A
- MNOV N/A
- P/E Ratio
- EQ N/A
- MNOV N/A
- Revenue Growth
- EQ N/A
- MNOV N/A
- 52 Week Low
- EQ $0.27
- MNOV $1.13
- 52 Week High
- EQ $2.35
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- EQ 48.79
- MNOV 41.93
- Support Level
- EQ $1.78
- MNOV $1.25
- Resistance Level
- EQ $2.02
- MNOV $1.38
- Average True Range (ATR)
- EQ 0.26
- MNOV 0.04
- MACD
- EQ -0.09
- MNOV -0.01
- Stochastic Oscillator
- EQ 1.73
- MNOV 12.50
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.